newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was